EMA/97587/2021 
EndolucinBeta 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3 
amended 
on 
IB/0020 
B.I.a.1.z - Change in the manufacturer of AS or of a 
09/02/2021 
n/a 
starting material/reagent/intermediate for AS - Other 
variation 
IA/0021/G 
This was an application for a group of variations. 
08/02/2021 
n/a 
B.II.d.2.a - Change in test procedure for the finished 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
 
 
 
 
 
 
 
product - Minor changes to an approved test 
procedure 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
R/0019 
Renewal of the marketing authorisation. 
10/12/2020 
08/02/2021 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
EndolucinBeta in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
PSUSA/10391
Periodic Safety Update EU Single assessment - 
23/07/2020 
24/09/2020 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/201912 
lutetium (177Lu) chloride 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10391/201912. 
IB/0017 
B.II.d.2.d - Change in test procedure for the finished 
05/08/2020 
n/a 
product - Other changes to a test procedure 
(including replacement or addition) 
IB/0016/G 
This was an application for a group of variations. 
15/07/2020 
n/a 
B.I.a.1.z - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - Other 
variation 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
IAIN/0018/G 
This was an application for a group of variations. 
29/06/2020 
24/09/2020 
SmPC, Annex 
A.1 - Administrative change - Change in the name 
and/or address of the MAH 
II, Labelling 
and PL 
EndolucinBeta  
EMA/97587/2021 
Page 2/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
A.5.a - Administrative change - Change in the name 
and/or address of a manufacturer/importer 
responsible for batch release 
IB/0015 
B.II.c.2.d - Change in test procedure for an excipient 
25/05/2020 
n/a 
- Other changes to a test procedure (including 
replacement or addition) 
IB/0013/G 
This was an application for a group of variations. 
06/12/2019 
n/a 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.1.z - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Other variation 
PSUSA/10391
Periodic Safety Update EU Single assessment - 
25/07/2019 
23/09/2019 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/201812 
lutetium (177Lu) chloride 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10391/201812. 
IA/0012/G 
This was an application for a group of variations. 
11/09/2019 
n/a 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
EndolucinBeta  
EMA/97587/2021 
Page 3/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
of the AS 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.II.c.1.c - Change in the specification parameters 
and/or limits of an excipient - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
IA/0011/G 
This was an application for a group of variations. 
29/05/2019 
n/a 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
PSUSA/10391
Periodic Safety Update EU Single assessment - 
31/01/2019 
28/03/2019 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/201806 
lutetium (177Lu) chloride 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10391/201806. 
IB/0009 
C.I.11.z - Introduction of, or change(s) to, the 
18/02/2019 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
PSUSA/10391
Periodic Safety Update EU Single assessment - 
26/07/2018 
20/09/2018 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/201712 
lutetium (177Lu) chloride 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10391/201712. 
EndolucinBeta  
EMA/97587/2021 
Page 4/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10391
Periodic Safety Update EU Single assessment - 
25/01/2018 
27/03/2018 
Refer to Scientific conclusions and grounds recommending 
/201706 
lutetium (177Lu) chloride 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10391/201706. 
IB/0006 
B.I.a.1.z - Change in the manufacturer of AS or of a 
21/02/2018 
n/a 
starting material/reagent/intermediate for AS - Other 
variation 
IB/0005 
C.I.11.z - Introduction of, or change(s) to, the 
06/01/2018 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
PSUSA/10391
Periodic Safety Update EU Single assessment - 
20/07/2017 
21/09/2017 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/201612 
lutetium (177Lu) chloride 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10391/201612. 
IA/0003/G 
This was an application for a group of variations. 
28/07/2017 
n/a 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
IB/0002 
B.II.b.4.a - Change in the batch size (including batch 
24/05/2017 
n/a 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
EndolucinBeta  
EMA/97587/2021 
Page 5/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
